There are currently 1500 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
Recruiting
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: Liver Center of Texas, Dallas, Texas
Conditions: Cancer, Liver Cirrhosis, Chronic Hepatitis, Hepatitis B, Hepatitis C, Diabetes, COPD
Genetic and Metabolic Disease in Children
Recruiting
This is a prospective, non-randomized, non-blinded observational study. The overarching goal is to discover new disease-associated genes in children, while establishing a specific focus on disorders where molecular characterization is most likely to lead to novel therapies. This study will merge detailed phenotypic characterization of patients presenting to the Pediatric Genetics and Metabolism Division in the Department of Pediatrics/Children's Medical Center at Dallas and collaborating clinics... Read More
Gender:
ALL
Ages:
1 day and above
Trial Updated:
06/12/2024
Locations: Children's Medical Center at Dallas, Dallas, Texas
Conditions: Genetic Diseases, Metabolic Diseases
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Recruiting
The main objectives of this study are to determine the feasibility and safety of AU-011 treatment of bladder cancer utilizing intratumoral injection with or without intramural injection and with or without laser application.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Non-muscle-invasive Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Heat Therapy in Older Hypertensive Women
Recruiting
The prevalence of hypertension is greater in older women than men, while the blood pressure (BP) control rate is lower in older women in US. Uncontrolled hypertension is a major risk factor for cardiovascular morbidity/mortality. Despite standard therapy and adherence to optimal drug regimens, \>50% of older hypertensive women still have inadequate BP control, and the control rate is further reduced with more aggressive BP targets recommended recently by the new Hypertension Guidelines. Thus, th... Read More
Gender:
FEMALE
Ages:
Between 65 years and 85 years
Trial Updated:
06/10/2024
Locations: Institute for Exercise and Environmental Medicine, Dallas, Texas
Conditions: Essential Hypertension
Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)
Recruiting
A multi-center, randomized, 72-month, parallel- group, non-inferiority, phase III study to compare the effectiveness of roflumilast (Daliresp, 500 mcg quaque die (QD) or alternate regimen) therapy versus azithromycin (250 mg QD, 500 mg QD three times per week, or alternate regimen) to prevent hospitalization or death in a patients at high risk for COPD exacerbations.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
06/06/2024
Locations: Baylor Scott & White (BSW) Health-North, Dallas, Texas
Conditions: Chronic Obstructive Pulmonary Disease Severe, Chronic Bronchitis
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
Recruiting
The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/05/2024
Locations: Baylor Research Institute, Dallas, Texas
Conditions: Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases
89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
Recruiting
This is an exploratory clinical trial to assess the potential of 89Zr-DFO-Atezolizumab Positron Emission Tomography/Computed Tomography (PET/CT) scans in patients with locally advanced or metastatic renal cell carcinoma (RCC). This open label, nontherapeutic trial will test the correlation of 89Zr-DFO-Atezolizumab immunoPET/CT with programmed death-ligand 1 (PD-L1) expression and the response to immune checkpoint inhibitor therapy in patients with RCC. There will be two cohorts, one made up of p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Renal Cell Carcinoma
Functional Assessment in Liver Transplantation
Recruiting
This will be a prospective cohort study of patients with liver disease. Subjects will undergo geriatric assessments of frailty, functional status, and disability using functional status measures at baseline and at every clinic visit in the pre-transplant setting. Subjects will also answer questions regarding quality of life, personality, and/or cognitive function. Subjects will again undergo assessments at every clinic visit through 12 months after transplant. Then, they will be followed annuall... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: Baylor Scott & White Health, Dallas, Texas
Conditions: End Stage Liver Disease
Eliminating Monitor Overuse Trial (EMO Trial)
Recruiting
The purpose of this study is to identify the optimal deimplementation strategies for an overused practice: continuous pulse oximetry monitoring of children hospitalized with bronchiolitis who are not receiving supplemental oxygen.
Gender:
ALL
Ages:
2 months and above
Trial Updated:
06/03/2024
Locations: Children's Medical Center Dallas, Dallas, Texas
Conditions: Bronchiolitis Acute Viral
PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
Recruiting
A prospective, single-arm, multi-center study designed to gather additional information on the LimFlow System.
Gender:
ALL
Ages:
Between 18 years and 95 years
Trial Updated:
05/31/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Critical Limb Ischemia, Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia
Dystonia Genotype-Phenotype Correlation
Recruiting
The purpose of this study is to (1) investigate the effect of known dystonia-causing mutations on brain structure and function, to (2) identify structural brain changes that differ between clinical phenotypes of dystonia, and to (3) collect DNA, detailed family history, and clinical phenotypes from patients with idiopathic dystonia with the goal of identifying new dystonia-related genes. Investigators will be recruiting both healthy control subjects and subjects with any form of dystonia. For th... Read More
Gender:
ALL
Ages:
11 years and above
Trial Updated:
05/31/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Dystonia, Dystonia; Idiopathic, Dystonia, Primary, Dystonia, Secondary, Dystonia, Familial, Dystonia Disorder, Dystonias, Sporadic, Dystonia; Orofacial, Dystonia Lenticularis, Dystonia, Paroxysmal, Dystonia 6, Dystonia 5, Dystonia 8, Dystonia 9, Dystonia 19, Dystonia 10, Dystonia 11, Dystonia 20, Dystonia 12, Dystonia, Focal, Dystonia of Head, Dystonia, Diurnal
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications
Recruiting
This registry is a prospective, multicenter, international, single arm, observational post-approval registry with follow-up at 3, 6, and 12 months, and annually for 5 years. The proposed registry will enroll 60 subjects and will be conducted at approximately 10 centers worldwide.
Gender:
ALL
Ages:
Between 30 years and 99 years
Trial Updated:
05/30/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Movement Disorders, Neurology, Parkinsons Disease